nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—Triamcinolone—multiple sclerosis	0.323	0.424	CbGbCtD
Tafluprost—PTGS2—Betamethasone—multiple sclerosis	0.277	0.364	CbGbCtD
Tafluprost—PTGS2—Dexamethasone—multiple sclerosis	0.161	0.212	CbGbCtD
Tafluprost—PTGFR—Small Ligand GPCRs—S1PR1—multiple sclerosis	0.0152	0.0959	CbGpPWpGaD
Tafluprost—PTGFR—Prostanoid ligand receptors—PTGER4—multiple sclerosis	0.0139	0.0882	CbGpPWpGaD
Tafluprost—PTGFR—Eicosanoid ligand-binding receptors—PTGER4—multiple sclerosis	0.00927	0.0586	CbGpPWpGaD
Tafluprost—PTGFR—Small Ligand GPCRs—PTGER4—multiple sclerosis	0.00767	0.0485	CbGpPWpGaD
Tafluprost—PTGFR—Small Ligand GPCRs—CNR1—multiple sclerosis	0.00665	0.0421	CbGpPWpGaD
Tafluprost—Visual acuity reduced—Fingolimod—multiple sclerosis	0.00638	0.0926	CcSEcCtD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.00532	0.0337	CbGpPWpGaD
Tafluprost—Uveitis—Azathioprine—multiple sclerosis	0.005	0.0727	CcSEcCtD
Tafluprost—PTGS2—S1P1 pathway—S1PR1—multiple sclerosis	0.00495	0.0313	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Other—S1PR1—multiple sclerosis	0.00433	0.0274	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTPRK—multiple sclerosis	0.00377	0.0238	CbGpPWpGaD
Tafluprost—Eye pain—Fingolimod—multiple sclerosis	0.00305	0.0443	CcSEcCtD
Tafluprost—Conjunctival hyperaemia—Prednisolone—multiple sclerosis	0.00264	0.0383	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TBX21—multiple sclerosis	0.00243	0.0154	CbGpPWpGaD
Tafluprost—Conjunctival hyperaemia—Betamethasone—multiple sclerosis	0.0022	0.032	CcSEcCtD
Tafluprost—Conjunctival hyperaemia—Dexamethasone—multiple sclerosis	0.0022	0.032	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Other—CXCR3—multiple sclerosis	0.00212	0.0134	CbGpPWpGaD
Tafluprost—Endophthalmitis—Betamethasone—multiple sclerosis	0.00203	0.0295	CcSEcCtD
Tafluprost—Endophthalmitis—Dexamethasone—multiple sclerosis	0.00203	0.0295	CcSEcCtD
Tafluprost—PTGFR—G alpha (q) signalling events—GPR65—multiple sclerosis	0.00196	0.0124	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Other—CNR1—multiple sclerosis	0.0019	0.012	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—multiple sclerosis	0.00178	0.0113	CbGpPWpGaD
Tafluprost—Eye disorder—Fingolimod—multiple sclerosis	0.00178	0.0259	CcSEcCtD
Tafluprost—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.00177	0.159	CbGdCrCtD
Tafluprost—Endophthalmitis—Prednisone—multiple sclerosis	0.00177	0.0257	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	0.00176	0.0111	CbGpPWpGaD
Tafluprost—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.00175	0.156	CbGdCrCtD
Tafluprost—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.00175	0.156	CbGdCrCtD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.00174	0.011	CbGpPWpGaD
Tafluprost—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.00171	0.153	CbGdCrCtD
Tafluprost—Visual acuity reduced—Dexamethasone—multiple sclerosis	0.00163	0.0236	CcSEcCtD
Tafluprost—Visual acuity reduced—Betamethasone—multiple sclerosis	0.00163	0.0236	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.00161	0.0102	CbGpPWpGaD
Tafluprost—Vision blurred—Fingolimod—multiple sclerosis	0.00156	0.0227	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.00152	0.0096	CbGpPWpGaD
Tafluprost—Cough—Fingolimod—multiple sclerosis	0.00145	0.021	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	0.00144	0.00913	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.00139	0.00878	CbGpPWpGaD
Tafluprost—Eye irritation—Prednisolone—multiple sclerosis	0.00136	0.0197	CcSEcCtD
Tafluprost—Nervous system disorder—Fingolimod—multiple sclerosis	0.00133	0.0193	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Other—CCR5—multiple sclerosis	0.00133	0.00839	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.0013	0.00822	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—S1PR1—multiple sclerosis	0.00123	0.00777	CbGpPWpGaD
Tafluprost—Dyspnoea—Fingolimod—multiple sclerosis	0.00121	0.0175	CcSEcCtD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—multiple sclerosis	0.00119	0.00756	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00119	0.00752	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00119	0.00752	CbGpPWpGaD
Tafluprost—Urinary tract infection—Cladribine—multiple sclerosis	0.00117	0.017	CcSEcCtD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—multiple sclerosis	0.00116	0.00735	CbGpPWpGaD
Tafluprost—Cataract—Triamcinolone—multiple sclerosis	0.00112	0.0163	CcSEcCtD
Tafluprost—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.00107	0.0958	CbGdCrCtD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—multiple sclerosis	0.00106	0.00673	CbGpPWpGaD
Tafluprost—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.00105	0.0942	CbGdCrCtD
Tafluprost—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.00105	0.0942	CbGdCrCtD
Tafluprost—PTGS2—Spinal Cord Injury—MBP—multiple sclerosis	0.00104	0.00657	CbGpPWpGaD
Tafluprost—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.00103	0.0921	CbGdCrCtD
Tafluprost—Cataract—Betamethasone—multiple sclerosis	0.00102	0.0148	CcSEcCtD
Tafluprost—Cataract—Dexamethasone—multiple sclerosis	0.00102	0.0148	CcSEcCtD
Tafluprost—Eye disorder—Cladribine—multiple sclerosis	0.00101	0.0147	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	0.000993	0.00628	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—GPR65—multiple sclerosis	0.00099	0.00626	CbGpPWpGaD
Tafluprost—Pruritus—Fingolimod—multiple sclerosis	0.000957	0.0139	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000952	0.00602	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000919	0.00581	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL13—multiple sclerosis	0.000905	0.00573	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCR1—multiple sclerosis	0.000905	0.00573	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000894	0.00566	CbGpPWpGaD
Tafluprost—Dry eye—Dexamethasone—multiple sclerosis	0.000893	0.013	CcSEcCtD
Tafluprost—Dry eye—Betamethasone—multiple sclerosis	0.000893	0.013	CcSEcCtD
Tafluprost—Cataract—Prednisone—multiple sclerosis	0.000885	0.0129	CcSEcCtD
Tafluprost—Headache—Fingolimod—multiple sclerosis	0.000848	0.0123	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000847	0.00536	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000825	0.00522	CbGpPWpGaD
Tafluprost—Cough—Cladribine—multiple sclerosis	0.00082	0.0119	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000815	0.00516	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000787	0.00498	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—AQP4—multiple sclerosis	0.000787	0.00498	CbGpPWpGaD
Tafluprost—Eye pain—Dexamethasone—multiple sclerosis	0.000778	0.0113	CcSEcCtD
Tafluprost—Eye pain—Betamethasone—multiple sclerosis	0.000778	0.0113	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	0.000773	0.00489	CbGpPWpGaD
Tafluprost—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.000768	0.0112	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000766	0.00485	CbGpPWpGaD
Tafluprost—Nervous system disorder—Cladribine—multiple sclerosis	0.000752	0.0109	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	0.000752	0.00475	CbGpPWpGaD
Tafluprost—Rhinitis—Mitoxantrone—multiple sclerosis	0.000711	0.0103	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000707	0.00447	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—multiple sclerosis	0.000702	0.00444	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000694	0.00439	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	0.000689	0.00436	CbGpPWpGaD
Tafluprost—Dyspnoea—Cladribine—multiple sclerosis	0.000684	0.00994	CcSEcCtD
Tafluprost—PTGS2—S1P1 pathway—MAPK1—multiple sclerosis	0.00067	0.00424	CbGpPWpGaD
Tafluprost—Asthma—Triamcinolone—multiple sclerosis	0.000669	0.00972	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CCL3—multiple sclerosis	0.000645	0.00408	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	0.000638	0.00403	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000636	0.00403	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—S1PR1—multiple sclerosis	0.00063	0.00399	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.00063	0.00398	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	0.000624	0.00395	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTGER4—multiple sclerosis	0.000621	0.00393	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCR3—multiple sclerosis	0.0006	0.00379	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—RGS1—multiple sclerosis	0.00059	0.00373	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCR2—multiple sclerosis	0.000583	0.00369	CbGpPWpGaD
Tafluprost—Vision blurred—Mitoxantrone—multiple sclerosis	0.000582	0.00846	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000576	0.00364	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GPR65—multiple sclerosis	0.000559	0.00354	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000548	0.00347	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	0.000545	0.00345	CbGpPWpGaD
Tafluprost—Pruritus—Cladribine—multiple sclerosis	0.000543	0.00789	CcSEcCtD
Tafluprost—Cough—Mitoxantrone—multiple sclerosis	0.000539	0.00783	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CNR1—multiple sclerosis	0.000538	0.00341	CbGpPWpGaD
Tafluprost—Rhinitis—Triamcinolone—multiple sclerosis	0.000537	0.0078	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—RGS1—multiple sclerosis	0.000536	0.00339	CbGpPWpGaD
Tafluprost—Rhinitis—Methylprednisolone—multiple sclerosis	0.000536	0.00778	CcSEcCtD
Tafluprost—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000515	0.00325	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000512	0.00324	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCR1—multiple sclerosis	0.000512	0.00324	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GPR65—multiple sclerosis	0.000508	0.00321	CbGpPWpGaD
Tafluprost—Eye disorder—Methylprednisolone—multiple sclerosis	0.000499	0.00725	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000494	0.00312	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LINGO1—multiple sclerosis	0.000491	0.00311	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL10—multiple sclerosis	0.000485	0.00307	CbGpPWpGaD
Tafluprost—Headache—Cladribine—multiple sclerosis	0.000481	0.00698	CcSEcCtD
Tafluprost—Vision blurred—Prednisolone—multiple sclerosis	0.000478	0.00694	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CXCL13—multiple sclerosis	0.000465	0.00294	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCR1—multiple sclerosis	0.000465	0.00294	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000463	0.00293	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	0.000454	0.00287	CbGpPWpGaD
Tafluprost—Eye disorder—Betamethasone—multiple sclerosis	0.000454	0.0066	CcSEcCtD
Tafluprost—Eye disorder—Dexamethasone—multiple sclerosis	0.000454	0.0066	CcSEcCtD
Tafluprost—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	0.000453	0.00287	CbGpPWpGaD
Tafluprost—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000449	0.00653	CcSEcCtD
Tafluprost—Asthma—Methotrexate—multiple sclerosis	0.000442	0.00642	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—TAGAP—multiple sclerosis	0.000426	0.00269	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCL5—multiple sclerosis	0.000417	0.00264	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	0.000407	0.00258	CbGpPWpGaD
Tafluprost—Cough—Triamcinolone—multiple sclerosis	0.000407	0.00591	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	0.000404	0.00255	CbGpPWpGaD
Tafluprost—Eye disorder—Prednisone—multiple sclerosis	0.000395	0.00574	CcSEcCtD
Tafluprost—Headache—Azathioprine—multiple sclerosis	0.000391	0.00568	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000386	0.00244	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.00038	0.0024	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	0.000378	0.00239	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000377	0.00239	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCR5—multiple sclerosis	0.000376	0.00238	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—S1PR1—multiple sclerosis	0.000372	0.00235	CbGpPWpGaD
Tafluprost—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000372	0.00541	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—GPC5—multiple sclerosis	0.000362	0.00229	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000351	0.00222	CbGpPWpGaD
Tafluprost—Vision blurred—Prednisone—multiple sclerosis	0.000347	0.00504	CcSEcCtD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000347	0.00219	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000347	0.00219	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000345	0.00218	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.00034	0.00215	CbGpPWpGaD
Tafluprost—Dyspnoea—Triamcinolone—multiple sclerosis	0.000339	0.00493	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000339	0.00214	CbGpPWpGaD
Tafluprost—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000338	0.00492	CcSEcCtD
Tafluprost—Nervous system disorder—Betamethasone—multiple sclerosis	0.000338	0.00492	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000337	0.00213	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL3—multiple sclerosis	0.000331	0.00209	CbGpPWpGaD
Tafluprost—Eye disorder—Methotrexate—multiple sclerosis	0.00033	0.0048	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.00033	0.00209	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCR2—multiple sclerosis	0.00033	0.00209	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTGER4—multiple sclerosis	0.000319	0.00202	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000317	0.002	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RGS1—multiple sclerosis	0.000316	0.002	CbGpPWpGaD
Tafluprost—Headache—Mitoxantrone—multiple sclerosis	0.000316	0.00459	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000314	0.00199	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	0.000313	0.00198	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCR3—multiple sclerosis	0.000308	0.00195	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CNR1—multiple sclerosis	0.000304	0.00192	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	0.0003	0.0019	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GPR65—multiple sclerosis	0.0003	0.0019	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCR2—multiple sclerosis	0.000299	0.00189	CbGpPWpGaD
Tafluprost—Nervous system disorder—Prednisone—multiple sclerosis	0.000295	0.00428	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000295	0.00186	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	0.000294	0.00186	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—POMC—multiple sclerosis	0.000294	0.00186	CbGpPWpGaD
Tafluprost—Vision blurred—Methotrexate—multiple sclerosis	0.00029	0.00421	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	0.00029	0.00183	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000289	0.00183	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCL2—multiple sclerosis	0.000287	0.00182	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000277	0.00175	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CNR1—multiple sclerosis	0.000276	0.00175	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL13—multiple sclerosis	0.000274	0.00174	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCR1—multiple sclerosis	0.000274	0.00174	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000274	0.00173	CbGpPWpGaD
Tafluprost—Pruritus—Triamcinolone—multiple sclerosis	0.000269	0.00391	CcSEcCtD
Tafluprost—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	0.000269	0.0017	CbGpPWpGaD
Tafluprost—Cough—Methotrexate—multiple sclerosis	0.000269	0.0039	CcSEcCtD
Tafluprost—Pruritus—Methylprednisolone—multiple sclerosis	0.000269	0.0039	CcSEcCtD
Tafluprost—Headache—Prednisolone—multiple sclerosis	0.000259	0.00377	CcSEcCtD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	0.000258	0.00163	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL10—multiple sclerosis	0.000249	0.00157	CbGpPWpGaD
Tafluprost—Nervous system disorder—Methotrexate—multiple sclerosis	0.000246	0.00358	CcSEcCtD
Tafluprost—Pruritus—Betamethasone—multiple sclerosis	0.000244	0.00355	CcSEcCtD
Tafluprost—Pruritus—Dexamethasone—multiple sclerosis	0.000244	0.00355	CcSEcCtD
Tafluprost—Headache—Triamcinolone—multiple sclerosis	0.000238	0.00346	CcSEcCtD
Tafluprost—Headache—Methylprednisolone—multiple sclerosis	0.000238	0.00345	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000237	0.0015	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCL5—multiple sclerosis	0.000236	0.00149	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	0.000229	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000226	0.00143	CbGpPWpGaD
Tafluprost—Dyspnoea—Methotrexate—multiple sclerosis	0.000224	0.00325	CcSEcCtD
Tafluprost—PTGS2—Metabolism—SRM—multiple sclerosis	0.000219	0.00139	CbGpPWpGaD
Tafluprost—Headache—Betamethasone—multiple sclerosis	0.000216	0.00314	CcSEcCtD
Tafluprost—Headache—Dexamethasone—multiple sclerosis	0.000216	0.00314	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—CCL5—multiple sclerosis	0.000214	0.00135	CbGpPWpGaD
Tafluprost—Pruritus—Prednisone—multiple sclerosis	0.000213	0.00309	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—CCR5—multiple sclerosis	0.000212	0.00134	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000209	0.00132	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	0.000208	0.00132	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	0.000204	0.00129	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	0.000203	0.00128	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL3—multiple sclerosis	0.000196	0.00124	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCR5—multiple sclerosis	0.000193	0.00122	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	0.000192	0.00122	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL2RA—multiple sclerosis	0.00019	0.0012	CbGpPWpGaD
Tafluprost—Headache—Prednisone—multiple sclerosis	0.000188	0.00274	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—PTGER4—multiple sclerosis	0.000188	0.00119	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	0.000187	0.00118	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PGR—multiple sclerosis	0.000185	0.00117	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCR3—multiple sclerosis	0.000182	0.00115	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CD28—multiple sclerosis	0.00018	0.00114	CbGpPWpGaD
Tafluprost—Pruritus—Methotrexate—multiple sclerosis	0.000178	0.00258	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—CCR2—multiple sclerosis	0.000177	0.00112	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GPC5—multiple sclerosis	0.000169	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—POMC—multiple sclerosis	0.000166	0.00105	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CNR1—multiple sclerosis	0.000163	0.00103	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	0.000159	0.001	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	0.000158	0.001	CbGpPWpGaD
Tafluprost—Headache—Methotrexate—multiple sclerosis	0.000157	0.00229	CcSEcCtD
Tafluprost—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	0.000155	0.000983	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP24A1—multiple sclerosis	0.000154	0.000977	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP27B1—multiple sclerosis	0.000154	0.000977	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000151	0.000955	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	0.000151	0.000955	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—POMC—multiple sclerosis	0.000151	0.000954	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	0.000148	0.000936	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL2—multiple sclerosis	0.000148	0.000933	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL10—multiple sclerosis	0.000147	0.000929	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPC5—multiple sclerosis	0.000141	0.000894	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—TYK2—multiple sclerosis	0.000134	0.000847	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CD86—multiple sclerosis	0.000128	0.000813	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL5—multiple sclerosis	0.000126	0.0008	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IL2—multiple sclerosis	0.000123	0.000776	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	0.000119	0.000755	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SPP1—multiple sclerosis	0.000117	0.000741	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—RRM1—multiple sclerosis	0.000117	0.000741	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCR5—multiple sclerosis	0.000114	0.000721	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL2RA—multiple sclerosis	0.000112	0.00071	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL2—multiple sclerosis	0.000111	0.000705	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPL5—multiple sclerosis	0.00011	0.000694	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000108	0.000683	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000108	0.000682	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000106	0.000669	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC11A1—multiple sclerosis	0.000105	0.000665	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APOE—multiple sclerosis	0.000104	0.000656	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000101	0.000637	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CD80—multiple sclerosis	9.37e-05	0.000593	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.08e-05	0.000575	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—POMC—multiple sclerosis	8.91e-05	0.000563	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL2—multiple sclerosis	8.71e-05	0.000551	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MAPK1—multiple sclerosis	8.53e-05	0.000539	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD28—multiple sclerosis	8.39e-05	0.000531	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TYK2—multiple sclerosis	7.91e-05	0.000501	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.8e-05	0.000494	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.11e-05	0.00045	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—BCHE—multiple sclerosis	6.72e-05	0.000425	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL2—multiple sclerosis	6.58e-05	0.000416	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—multiple sclerosis	6.55e-05	0.000414	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP9—multiple sclerosis	6.23e-05	0.000394	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD86—multiple sclerosis	5.99e-05	0.000379	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—STAT3—multiple sclerosis	5.54e-05	0.00035	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CCR5—multiple sclerosis	5.31e-05	0.000336	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HLA-A—multiple sclerosis	5.17e-05	0.000327	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—multiple sclerosis	5.15e-05	0.000326	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TGFB1—multiple sclerosis	5.14e-05	0.000325	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK1—multiple sclerosis	5.04e-05	0.000319	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOE—multiple sclerosis	4.83e-05	0.000306	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD80—multiple sclerosis	4.37e-05	0.000276	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—APOE—multiple sclerosis	4.05e-05	0.000256	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—multiple sclerosis	3.87e-05	0.000245	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TYK2—multiple sclerosis	3.69e-05	0.000233	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—POMC—multiple sclerosis	3.48e-05	0.00022	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD4—multiple sclerosis	3.33e-05	0.000211	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALB—multiple sclerosis	3.17e-05	0.0002	CbGpPWpGaD
Tafluprost—PTGS2—Disease—STAT3—multiple sclerosis	2.58e-05	0.000163	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—multiple sclerosis	2.4e-05	0.000152	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFB1—multiple sclerosis	2.39e-05	0.000151	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MAPK1—multiple sclerosis	2.35e-05	0.000148	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—multiple sclerosis	1.8e-05	0.000114	CbGpPWpGaD
